Barclays Maintains Overweight on Elanco Animal Health, Lowers Price Target to $21
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Balaji Prasad maintains an Overweight rating on Elanco Animal Health (NYSE:ELAN) but lowers the price target from $23 to $21.
June 28, 2024 | 3:46 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Barclays analyst Balaji Prasad maintains an Overweight rating on Elanco Animal Health but lowers the price target from $23 to $21.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100